Natixis Advisors L.P. Sells 9,270 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Posted by Defense World Staff on Apr 15th, 2023

Natixis Advisors L.P. lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 13.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 61,192 shares of the company’s stock after selling 9,270 shares during the period. Natixis Advisors L.P. owned approximately 0.06% of Neurocrine Biosciences worth $7,309,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Acadian Asset Management LLC bought a new stake in Neurocrine Biosciences during the 1st quarter worth approximately $27,000. Covestor Ltd grew its stake in Neurocrine Biosciences by 431.0% in the 1st quarter. Covestor Ltd now owns 377 shares of the company’s stock worth $35,000 after buying an additional 306 shares in the last quarter. Piershale Financial Group Inc. purchased a new position in Neurocrine Biosciences in the 4th quarter worth approximately $36,000. C M Bidwell & Associates Ltd. purchased a new position in Neurocrine Biosciences in the 3rd quarter worth approximately $45,000. Finally, CENTRAL TRUST Co purchased a new position in Neurocrine Biosciences in the 3rd quarter worth approximately $45,000. Institutional investors own 92.58% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Kevin Charles Gorman sold 2,707 shares of the stock in a transaction dated Tuesday, January 31st. The shares were sold at an average price of $110.08, for a total value of $297,986.56. Following the completion of the transaction, the chief executive officer now directly owns 465,278 shares in the company, valued at approximately $51,217,802.24. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Kevin Charles Gorman sold 2,707 shares of the business’s stock in a transaction dated Tuesday, January 31st. The shares were sold at an average price of $110.08, for a total transaction of $297,986.56. Following the sale, the chief executive officer now owns 465,278 shares of the company’s stock, valued at $51,217,802.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Neurocrine Biosciences Inc acquired 4,395,588 shares of the company’s stock in a transaction that occurred on Thursday, February 23rd. The shares were acquired at an average cost of $8.88 per share, for a total transaction of $39,032,821.44. Following the purchase, the insider now directly owns 8,575,316 shares of the company’s stock, valued at $76,148,806.08. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 39,349 shares of company stock worth $4,091,023. 4.40% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Trading Down 1.0 %

Shares of NASDAQ NBIX opened at $102.78 on Friday. Neurocrine Biosciences, Inc. has a 12 month low of $75.25 and a 12 month high of $129.29. The firm has a market capitalization of $10.02 billion, a PE ratio of 67.18 and a beta of 0.49. The firm has a fifty day simple moving average of $100.44 and a two-hundred day simple moving average of $110.03.

Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) last issued its quarterly earnings data on Monday, February 6th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.15 by $0.09. Neurocrine Biosciences had a net margin of 10.38% and a return on equity of 10.19%. The business had revenue of $412.00 million during the quarter, compared to analyst estimates of $408.96 million. During the same period in the prior year, the business earned ($0.08) EPS. The company’s revenue for the quarter was up 32.1% on a year-over-year basis. On average, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 2.77 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on NBIX. Canaccord Genuity Group raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $124.00 to $132.00 in a research note on Thursday, March 30th. StockNews.com initiated coverage on shares of Neurocrine Biosciences in a research note on Thursday, March 16th. They issued a “strong-buy” rating for the company. UBS Group cut their price objective on shares of Neurocrine Biosciences from $137.00 to $125.00 and set a “buy” rating for the company in a research note on Tuesday, April 4th. Citigroup cut their price objective on shares of Neurocrine Biosciences from $133.00 to $131.00 and set a “buy” rating for the company in a research note on Tuesday, February 7th. Finally, Barclays cut their price objective on shares of Neurocrine Biosciences from $136.00 to $131.00 and set an “overweight” rating for the company in a research note on Tuesday, February 7th. Five equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $125.39.

About Neurocrine Biosciences

(Get Rating)

Neurocrine Biosciences, Inc is a neuroscience-focused, biopharmaceutical company. It discovers, develops, and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.